Dementia

Dementia is not a specific disease. It is a descriptive term for a collection of symptoms that can be caused by a number of disorders that affect the brain. People with dementia have significantly impaired intellectual functioning that interferes with normal activities and relationships.

What Causes Dementia?

Dementia occurs due to loss of brain function that occurs with certain diseases. It can affect several brain functions such as memory, thinking, language, planning, behavior and judgement. Dementias are usually progressive and worsen with time. They usually are degenerative and non reversible.

What is Mixed Dementia?

Parkinson's Compared to Dementia with Lewy Bodies (DLB)

Transcutaneous Electrical Nerve Stimulation for Dementia

Antidepressants and Dementia: Is There a Link?

Bright Light Therapy and Dementia

Dementia Treatment

Aromatherapy for Dementia

Dementia Symptoms

Coconut Oil and Dementia

Mixed Dementia Symptoms and Diagnosis

Does Depression and Anxiety Increase the Risk of Dementia?

See more featured articles »

Dementia Prevention

Dementia with Lewy Bodies

Dementia Diagnosis

Differences Between Alzheimer's and Dementia

Childhood Dementia Causes

Migraines and Dementia

Mixed Dementia Prevention and Treatment

Childhood Dementia Signs and Symptoms

What is Dementia?

Latest Dementia News and Research

Grant fuels research into SYNGAP1-linked behavioral abnormalities

CURE SYNGAP1 501(c)(3) is pleased to announce a $130,000 grant to Dr. Helen Willsey and Dr. David Kastner at the University of California, San Francisco (UCSF).

5 Jun 2026

New artificial intelligence tool helps clinicians distinguish between dementia types

Alzheimer's disease and related dementias are expected to more than double by 2060. As June marks Alzheimer's and Brain Awareness Month, three University of Florida researchers are working to improve clinicians' ability to distinguish between these diseases - a critical step toward earlier diagnosis and better outcomes.

5 Jun 2026

Study links common sleep behaviors to signs of brain aging

How we sleep may have lasting impacts for our brain health as we age. A new University of Arizona study has found that several common sleep behaviors may be linked to signs of brain aging.

5 Jun 2026

Flu drugs may reduce cognitive decline in people with HIV

A class of flu drugs may reduce cognitive decline and premature aging in people living with chronic viral infection, reports a new study led by Northwestern University that began with blood samples from people with HIV and extended into preclinical drug trials.

5 Jun 2026

Favorable lifestyle factors reduce dementia risk across key genetic profiles

With dementia cases expected to nearly triple worldwide by 2050, researchers are increasingly focused on identifying ways to prevent or delay the disease.

5 Jun 2026

Senior Care Authority kicks off Alzheimer's and Brain Awareness Month with six science-backed habits that may help reduce dementia risk

An estimated 7.4 million Americans aged 65 and older are now living with Alzheimer's disease, according to the Alzheimer's Association's 2026 Alzheimer's Disease Facts and Figures report, and that number is projected to climb to nearly 13 million by 2050.

5 Jun 2026

What older adults eat may shape dementia risk

Higher ultraprocessed food intake was associated with increased risks of dementia, cognitive impairment with no dementia, and the combined outcome among older US adults in the Health and Retirement Study. Minimally processed food intake showed the opposite pattern, although the observational findings require cautious interpretation because diet was self-reported and cognitive outcomes were not clinically diagnosed.

4 Jun 2026

Microglia transitions act as critical turning point in Alzheimer's

Researchers from VIB, KU Leuven, the UK-DRI and Muna Therapeutics, funded by, among others, ERC, have uncovered a critical biological transition that may determine whether Alzheimer's disease pathology leads to dementia.

4 Jun 2026

Eight startups selected to advance heart and brain health technologies

Eight companies have been selected to participate in the American Heart Association Heart and Brain Health Accelerator, a specialty track within the 2026 MedTech Innovator (MTI) Accelerator.

4 Jun 2026

Higher genetic pulse pressure risk associated with dementia-related mortality

When looking at genetic variants in a person's DNA that predispose them to disease, a new study has found having a higher number of genetic variants for increased pulse pressure is associated with a small, increased risk of dementia as a contributing cause of death.

3 Jun 2026

Long-term exposure to air pollution associated with lower semantic memory

A new study by researchers at UC Davis Health and Kaiser Permanente found that higher exposure to very small air pollution particles (PM2.5) over a 17-year span was associated with lower semantic memory.

3 Jun 2026

The best foods for brain health may change as you age

Investigating brain foods, this review highlights dietary influences on cognition and neurodevelopment, while addressing significant gaps in current research.

3 Jun 2026

Is any level of alcohol safe? Major review reveals where drinking risks rise

This Burden of Proof review found that alcohol consumption is associated with higher risks for several cancers, liver disease, pancreatitis, lower respiratory infections, tuberculosis, and atrial fibrillation. Although low-to-moderate drinking showed modest observational links with lower risks of type 2 diabetes, dementia, and some cardiovascular outcomes, the evidence was weaker and potentially biased.

2 Jun 2026

AI-assisted model based on blood proteins could help predict retinal degeneration in diabetics

An AI-assisted model based on 71 different blood proteins could help doctors better predict retinal degeneration in diabetic patients before symptoms occur, according to a study published June 2nd in the open access journal PLOS Medicine by Huangdong Li from the Guangdong Provincial Clinical Research Center for Ocular Diseases in Guangzhou, China, and colleagues.

2 Jun 2026

Allen Institute launches global research initiative to accelerate new treatments for brain disorders

The Allen Institute, together with partner organizations, today launched the Brain Health accelerator: an ambitious global research initiative seeking to identify the specific brain cells and circuits affected in neurodegenerative disease and other brain disorders and use that knowledge to accelerate the development of new treatments.

2 Jun 2026

How dysregulated collagen IV homeostasis causes cerebral microbleeds

Millions of older adults have tiny brain hemorrhages called cerebral microbleeds, which are strongly associated with dementia, cognitive decline, and stroke.

2 Jun 2026

New reference models track lifespan changes in brain wiring

Researchers at the USC Mark and Mary Stevens Neuroimaging and Informatics Institute (Stevens INI) at the Keck School of Medicine of USC have created one of the largest reference models ever developed for the human brain, using diffusion MRI scans from more than 54,000 people to chart how the brain's communication pathways develop, mature, and decline across the lifespan.

2 Jun 2026

Cellular reprogramming helps outsmart progressive Alzheimers disease

A team led by researcher José Vicente Sánchez Mut at the Institute for Neurosciences (IN), a joint center of the Spanish National Research Council (CSIC) and the Miguel Hernández University of Elche (UMH), together with researcher Johannes Gräff at the École Polytechnique Fédérale de Lausanne (EPFL), has identified an experimental molecule capable of "reprogramming" the brain's immune cells to restore part of their protective function against Alzheimer's disease.

2 Jun 2026

Lower Alzheimer’s amyloid levels in Black and Latinx adults

Findings show lower amyloid PET positivity in Black and Latinx adults with cognitive impairment, highlighting disparities in dementia diagnosis and treatment.

1 Jun 2026

Why new Alzheimer’s drugs are dividing regulators worldwide

The Lancet World Report examines why regulators in the US, UK, and Europe have reached different decisions on new amyloid-targeting Alzheimer’s drugs despite evidence that they can modestly slow clinical decline. It highlights the unresolved balance among benefits, safety risks, costs, access, and the need for broader, earlier, and more patient-centered treatment strategies.

31 May 2026